Actively Recruiting
Molecular Signatures of Cutaneous Dupilumab Response
Led by University of California, San Francisco · Updated on 2024-06-27
15
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
CONDITIONS
Official Title
Molecular Signatures of Cutaneous Dupilumab Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Atopic dermatitis with an Eczema Area and Severity Index (EASI) score of 7 or higher
You will not qualify if you...
- Known pregnancy
- Known immunodeficiencies
- Known parasitic infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
J
Jeffrey Cheng, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here